Compare MLYS & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | RHI |
|---|---|---|
| Founded | 2019 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2023 | 1994 |
| Metric | MLYS | RHI |
|---|---|---|
| Price | $30.46 | $27.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $48.67 | $30.33 |
| AVG Volume (30 Days) | 1.3M | ★ 2.6M |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 8.94% |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ 1.33 |
| Revenue | N/A | ★ $5,378,506,000.00 |
| Revenue This Year | N/A | $1.27 |
| Revenue Next Year | N/A | $5.95 |
| P/E Ratio | ★ N/A | $19.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.59 | $21.83 |
| 52 Week High | $47.65 | $48.54 |
| Indicator | MLYS | RHI |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 59.56 |
| Support Level | $26.85 | $26.07 |
| Resistance Level | $31.09 | $28.35 |
| Average True Range (ATR) | 1.92 | 1.53 |
| MACD | 0.64 | 0.35 |
| Stochastic Oscillator | 89.85 | 77.28 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.